Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology

BMC Gastroenterology

Volumn 9, Issue , 2009, Pages 75-

  Chavez Tapia, Norberto C ^a   Tellez Avila, Felix I ^b   Bedogni, Giorgio ^a   Crocè, Lory S ^a,c   Masutti, Flora ^a   Tiribelli, Claudio ^a,c  

^a Bldg Q AREA Science Park Basovizza Campus   (Italy)

^b Nutrición Salvador Zubirán ^*  (Mexico)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; CALCULATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FATTY LIVER; HUMAN; LIVER DISEASE; MENTAL DISEASE; META ANALYSIS; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; OBESITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

FATTY LIVER; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PIPERIDINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CANNABINOID; TREATMENT OUTCOME;

EID: 70449514093     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-9-75     Document Type: Article

References (35)

1. Al Snih S, Ottenbacher KJ, Markides KS, Kuo YF, Eschbach K, Goodwin JS. The effect of obesity on disability vs mortality in older Americans. Archives of internal medicine 2007, 167(8):774-780. 10.1001/archinte.167.8.774, 17452539.
2. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. The New England journal of medicine 2006, 355(8):763-778. 10.1056/NEJMoa055643, 16926275.
3. Skilton MR, Moulin P, Serusclat A, Nony P, Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis 2007, 190(2):416-422. 10.1016/j.atherosclerosis.2006.02.019, 16616756.
4. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. Cmaj 2007, 176(8):S1-13. 1839777, 17420481.
5. Rubio MA, Gargallo M, Isabel Millan A, Moreno B. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public health nutrition 2007, 10(10A):1200-1205. 10.1017/S1368980007000717, 17903331.
6. Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, Rudilosso A, Ballestri S, Carulli N. Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics 2005, 22(Suppl 2):31-36. 10.1111/j.1365-2036.2005.02592.x, 16225469.
7. Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, Cassader M. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes care 2008, 31(3):562-568. 10.2337/dc07-1526, 18056890.
8. Bugianesi E, Bellentani S, Tiribelli C, Svegliati Baroni G, Croce LS, Gastaldelli A, Marchesini G, Perseghin G, Tell G. Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Annals of Hepatology 2008, 7(2):157-160.
9. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends in molecular medicine 2008, 14(2):72-81. 10.1016/j.molmed.2007.12.003, 18218340.
10. Marchesini G, Natale S, Manini R, Agostini F. Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Alimentary pharmacology & therapeutics 2005, 22(Suppl 2):37-39. 10.1111/j.1365-2036.2005.02593.x, 16225470.
11. Zhao G, Ford ES, Li C, Mokdad AH. Compliance with physical activity recommendations in US adults with diabetes. Diabet Med 2008, 25(2):221-227. 10.1111/j.1464-5491.2007.02332.x, 18201213.
12. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology (Baltimore, Md) 2008, 47(2):746-754. 10.1002/hep.22009, 18098321.
13. Despres JP, Ross R, Boka G, Almeras N, Lemieux I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arteriosclerosis, thrombosis, and vascular biology 2009, 29(3):416-423. 10.1161/ATVBAHA.108.176362, 19112166.
14. An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes. , http://clinicaltrials.gov/ct2/show/NCT00577148?term=fatty+liver&rank =39
15. An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes. , http://clinicaltrials.gov/ct2/show/NCT00576667?term=fatty+liver&rank =40
16. Banasch M, Goetze O, Schmidt WE, Meier JJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver Int 2007, 27(8):1152-1155. 10.1111/j.1478-3231.2007.01555.x, 17845546.
17. Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Seminars in liver disease 2008, 28(4):396-406. 10.1055/s-0028-1091984, 18956296.
18. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370(9600):1706-1713. 10.1016/S0140-6736(07)61721-8, 18022033.
19. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane database of systematic reviews (Online) 2006, (4):CD006162.
20. Lundh A, Gotzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC medical research methodology 2008, 8:22. 10.1186/1471-2288-8-22, 2375895, 18426565.
21. Centre TNC. Review Manager (RevMan). Version 5 for Windows edn 2008, Copenhagen: The Cochrane Collaboration.
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002, 21(11):1539-1558. 10.1002/sim.1186, 12111919.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed) 1997, 315(7109):629-634. 2127453, 9310563.
24. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365(9468):1389-1397. 10.1016/S0140-6736(05)66374-X, 15836887.
25. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Jama 2006, 295(7):761-775. 10.1001/jama.295.7.761, 16478899.
26. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England journal of medicine 2005, 353(20):2121-2134. 10.1056/NEJMoa044537, 16291982.
27. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368(9548):1660-1672. 10.1016/S0140-6736(06)69571-8, 17098084.
28. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Jama 2008, 299(13):1547-1560. 10.1001/jama.299.13.1547, 18387931.
29. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes care 2008, 31(Suppl 2):S229-240. 10.2337/dc08-s258, 18227491.
30. Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF. Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence: Results From a Placebo-Controlled, Double-Blind Trial. Journal of clinical psychopharmacology 2008, 28(3):317-324. 10.1097/JCP.0b013e318172b8bc, 18480689.
31. Sathyapalan T, Cho L, Kilpatrick ES, Coady AM, Atkin SL. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome: a randomised open labelled parallel study. Clinical endocrinology 2008, 69(6):931-5. 10.1111/j.1365-2265.2008.03260.x, 18410553.
32. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. The SERENADE Trial: Effects of Monotherapy with Rimonabant, the First Selective CB1 Receptor Antagonist, on Glycemic Control, Body Weight and Lipid Profile in Drug-naive Type 2 Diabetes. Diabetes care 2008, 31(11):2169-76. 10.2337/dc08-0386, 18678611.
33. Johansson K, Neovius K, Desantis SM, Rossner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009, 10(5):564-75. 10.1111/j.1467-789X.2009.00581.x, 19460116.
34. Bellentani S, Bedogni G, Tiribelli C. Liver and heart: a new link?. Journal of hepatology 2008, 49(2):300-302. 10.1016/j.jhep.2008.05.003, 18554746.
35. Lau DC. Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. Cmaj 2007, 176(8):1103-1106. 1839782, 17420493.